Business Insider

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, ...
Seeking Alpha

Biotech Analysis Central Model 10+ Portfolio Old Pick#17 And Removed: Tempest Therapeutics; Phase 3 Study May Proceed TPST-1120, TPST-1495 Data 2025 And Catalysts

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #17 is a biotech by the name of Tempest Therapeutics (TPST). I want to state that I have chosen to ...
Seeking Alpha

Biotech Analysis Central Model 10+ Portfolio Pick#18 Annovis Bio; 6-Month Path Forward Possible For Buntanetap In AD, Q1 2025 Phase 3 Study Initiation And Catalysts

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Pick #18 is a biotech by the name of Annovis Bio (ANVS)The reason why I wanted to go over this biotech next as ...
FierceBiotech

TCG Labs Soleil raises $400M for single-asset biotechs, expands R&D footprint to China

In collaboration with The Column Group, TCG Labs Soleil runs a venture-biotech model with its own R&D hub. (iStock/Getty Images Plus) TCG Labs Soleil has secured $400 million to boost the firm’s ...
Nasdaq

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

INDIANAPOLIS, Sept. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that ...
Mena FN

Platform Biotech Models Draw Investor Eyes As Drug-Delivery Markets Head Toward $410 Billion

Biotechnology organizations are turning in growing numbers to alternative strategies centered on strengthening the performance of already-approved drugs. Oncotelic Therapeutics is developing ...